“Intestine-Chip” Could Help Patients With Diseases Like Crohn’s

Salmonella and Food | Features | CDC
June 11, 2018
Is it eczema or psoriasis?;
June 12, 2018
Show all

“Intestine-Chip” Could Help Patients With Diseases Like Crohn’s

A new tool could determine which treatment is best for each individual patient.

Patients with debilitating gastrointestinal diseases like Crohn’s disease, ulcerative colitis, and irritable bowel syndrome often have to try several costly treatments before they find one that works for them. These drugs can cause individuals painful side effects or ultimately be ineffective for their personal conditions. However, a new testing tool called an “Intestine-Chip” could save patients this pain and cost.

Intestinal lining cells created from an individual’s adult stem cells can be placed on a chip and mirror what is happening inside that individual’s body, according to a study from researchers at the Cedars-Sinai Board of Governors Regenerative Medicine Institute and Emulate, Inc. in Boston.

So, instead of testing drugs within a patient, you could test them on the Intestine-Chip first, protecting the patient from needlessly experiencing negative side effects. This could also reduce the amount of drug used, the difficulty of the application, and potentially the cost of the testing. This study was recently published in the journal Cellular and Molecular Gastroenterology and Hepatology.


Not only would Intestine-Chip allow researchers to better test drugs for patients, it could also give researchers more control in studies of these cells. Because the cells are on a chip and in a controlled environment, researchers can more easily study how they interact with immune cells and blood cells (as well as drugs) and better understand cell function.

Read on: “Intestine-Chip” Could Help Patients With Diseases Like Crohn’s

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.